KRAS and neoplasm: We are now determining how these KRAS-containing exosomes function in in vivo tumor models, and we are characterizing patient serum exosomes using fluorescence-activated vesicle sorting (FAVS), a method that we developed to address whether their contents can be used to predict colon cancer progression.